Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Pasireotide (Signifor) vs Pegvisomant (Somavert)
An educational, source-based comparison of Pasireotide (Signifor) and Pegvisomant (Somavert) — how each peptide works, what it's researched for, and what to know before going deeper.
Multi-receptor somatostatin analog for Cushing's disease and acromegaly.
Cyclohexapeptide somatostatin analog binding somatostatin receptors SST1, 2, 3, and 5 (with highest affinity for SST5), suppressing ACTH in corticotroph adenomas and GH/IGF-1 in somatotroph tumors.
- Cushing's disease
- Acromegaly (LAR formulation)
- • FDA-approved.
- • Significant hyperglycemia risk requires glucose monitoring.
- • Bradycardia and QT prolongation possible.
Pegylated GH receptor antagonist for acromegaly.
Genetically engineered analog of human GH with site-directed mutations blocking functional dimerization of the GH receptor; pegylation extends half-life. Lowers IGF-1 without lowering GH.
- Acromegaly inadequately controlled by surgery, radiation, or somatostatin analogs
- • FDA-approved.
- • Monitor LFTs; tumor monitoring via MRI required.
- • Lipohypertrophy at injection sites.
Pasireotide (Signifor) vs Pegvisomant (Somavert) — Key differences
- Class: Pasireotide (Signifor) is classified as Somatostatin Analog · Endocrine, while Pegvisomant (Somavert) is GH Receptor Antagonist · Endocrine.
- Primary research focus: Pasireotide (Signifor) — cushing's disease; Pegvisomant (Somavert) — acromegaly inadequately controlled by surgery, radiation, or somatostatin analogs.
- Tag: FDA-Approved · Endocrine vs FDA-Approved · Endocrine.